Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulse Biosciences CS (NQ: PLSE )

17.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 17.14
Bid (Size) 16.55 (1)
Ask (Size) 19.44 (1)
Prev. Close 17.14
Today's Range 17.14 - 17.14
52wk Range 3.780 - 22.69
Shares Outstanding 54,902,942
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q2 2024
Pulse Biosciences just reported results for the second quarter of 2024. 
Via InvestorPlace
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga

Performance

YTD
+55.54%
+55.54%
1 Month
+9.52%
+9.52%
3 Month
+28.20%
+28.20%
6 Month
+59.59%
+59.59%
1 Year
+273.42%
+273.42%

More News

Read More
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
From Pulse Biosciences, Inc.
Via Business Wire
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024
Via InvestorPlace
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is 'Clouded By Fed's Concerns Over Labor Market,' Analyst Warns
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
S&P 500, Nasdaq Extend Record Highs; Dow Up Triple Digits
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Via Benzinga
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Pulse Biosciences Enhances Executive Leadership Team
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.